Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience

In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach. BACKGROUND: Patients with relapsed or re...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Marina, Liberati, Anna Marina, Rigacci, Luigi, Puccini, Benedetta, Pulsoni, Alessandro, Gini, Guido, Galieni, Piero, Fabbri, Alberto, Cantonetti, Maria, Pavone, Vincenzo, Bolis, Silvia, Botto, Barbara, Renzi, Daniela, Falchi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531864/
https://www.ncbi.nlm.nih.gov/pubmed/34690088
http://dx.doi.org/10.1016/j.clml.2021.09.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531864/
https://www.ncbi.nlm.nih.gov/pubmed/34690088
http://dx.doi.org/10.1016/j.clml.2021.09.018

Ejemplares similares